On November 20, 2023 NanOlogy LLC, a clinical-stage oncology company, reported that an abstract reporting interim results from its lung cancer trial has been accepted for poster presentation at the IASLC North America Conference on Lung Cancer (NACLC) being held December 1-3, 2023, at the Chicago Marriott Downtown Magnificent Mile (Press release, NanOlogy, NOV 20, 2023, View Source;utm_medium=rss&utm_campaign=nanology-announces-an-abstract-has-been-accepted-for-presentation-at-the-iaslc-north-america-conference-on-lung-cancer [SID1234637846]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract (PP01.111) entitled: "Phase 2a Intratumoral Large Surface Area Microparticle Paclitaxel in Stage 3/4 Lung Cancer" will be presented by Hiren Mehta, MD (University of Florida Health) during poster sessions on Saturday, December 2nd, and Sunday, December 3rd.

A press release summarizing presentation data will be issued following the conference.

The IASLC North America Conference on Lung Cancer (NACLC)